Method for detecting the antiaggregatory effect of vasoactive substances, specifically of inhibitors of phosphodiesterase and/or cyclooxygenase


Ontology type: sgo:Patent     


Patent Info

DATE

1991-01-08T00:00

AUTHORS

Klaus U. Weithmann , Dirk Seiffge

ABSTRACT

The antiaggregatory effect of phosphodiesterase inhibitors (A) and/or of cyclooxygenase inhibitors (B) is detected outside the human or animal body bysampling blood,addition of (A) and/or (B) to the blood sample--if not already present therein, in unchanged or in metabolized form, as a consequence of previous administration,where appropriate removal of the erythrocytes and leukocytes andinitiation--preferably by addition of an aggregation inducer--and measurement of the platelet aggregation,the method comprises (A) also being added--if only (B) has been administered or added up till then--or (B) also being added--if only (A) has been administered or added up till then--and at least one prostaglandin (C) being added, before, or no later than at, the initiation of the platelet aggregation, so that the initiation and measurement of the platelet aggregation takes place in the presence of the ternary combination of (A), (B), each in the unchanged or in metabolized form, and (C).Suitable as (A) are preferably compounds with a xanthine or pyrimidopyrimidine structure and as (B) is preferably O-acetylsalicylic acid. The method replaces elaborate and complicated tests on the human and animal body. More... »

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3048", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "name": "Klaus U. Weithmann", 
        "type": "Person"
      }, 
      {
        "name": "Dirk Seiffge", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/279799a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028958845", 
          "https://doi.org/10.1038/279799a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/194927b0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052048522", 
          "https://doi.org/10.1038/194927b0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1991-01-08T00:00", 
    "description": "

The antiaggregatory effect of phosphodiesterase inhibitors (A) and/or of cyclooxygenase inhibitors (B) is detected outside the human or animal body by

sampling blood,

addition of (A) and/or (B) to the blood sample--if not already present therein, in unchanged or in metabolized form, as a consequence of previous administration,

where appropriate removal of the erythrocytes and leukocytes and

initiation--preferably by addition of an aggregation inducer--and measurement of the platelet aggregation,

the method comprises (A) also being added--if only (B) has been administered or added up till then--or (B) also being added--if only (A) has been administered or added up till then--and at least one prostaglandin (C) being added, before, or no later than at, the initiation of the platelet aggregation, so that the initiation and measurement of the platelet aggregation takes place in the presence of the ternary combination of (A), (B), each in the unchanged or in metabolized form, and (C).

Suitable as (A) are preferably compounds with a xanthine or pyrimidopyrimidine structure and as (B) is preferably O-acetylsalicylic acid. The method replaces elaborate and complicated tests on the human and animal body.

", "id": "sg:patent.US-4983514-A", "keywords": [ "method", "vasoactive substance", "inhibitor", "phosphodiesterase", "Prostaglandin-Endoperoxide Synthases", "phosphodiesterase inhibitor", "cyclooxygenase inhibitor", "animal body", "sampling", "blood sample", "consequence", "removal", "Erythrocyte", "leukocyte", "initiation", "aggregation", "platelet aggregation", "IF", "prostaglandin", "measurement", "compound", "xanthine", "acid" ], "name": "Method for detecting the antiaggregatory effect of vasoactive substances, specifically of inhibitors of phosphodiesterase and/or cyclooxygenase", "recipient": [ { "id": "https://www.grid.ac/institutes/grid.420214.1", "type": "Organization" } ], "sameAs": [ "https://app.dimensions.ai/details/patent/US-4983514-A" ], "sdDataset": "patents", "sdDatePublished": "2019-04-18T10:26", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-uberresearch-data-patents-target-20190320-rc/data/sn-export/402f166718b70575fb5d4ffe01f064d1/0000100128-0000352499/json_export_02965.jsonl", "type": "Patent" } ]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.US-4983514-A'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.US-4983514-A'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.US-4983514-A'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.US-4983514-A'


 

This table displays all metadata directly associated to this object as RDF triples.

57 TRIPLES      15 PREDICATES      39 URIs      31 LITERALS      2 BLANK NODES

Subject Predicate Object
1 sg:patent.US-4983514-A schema:about anzsrc-for:3048
2 schema:author Ne949a5f9d9f34951a25cc366dcbffd1a
3 schema:citation sg:pub.10.1038/194927b0
4 sg:pub.10.1038/279799a0
5 schema:datePublished 1991-01-08T00:00
6 schema:description <p>The antiaggregatory effect of phosphodiesterase inhibitors (A) and/or of cyclooxygenase inhibitors (B) is detected outside the human or animal body by</p><p>sampling blood,</p><p>addition of (A) and/or (B) to the blood sample--if not already present therein, in unchanged or in metabolized form, as a consequence of previous administration,</p><p>where appropriate removal of the erythrocytes and leukocytes and</p><p>initiation--preferably by addition of an aggregation inducer--and measurement of the platelet aggregation,</p><p>the method comprises (A) also being added--if only (B) has been administered or added up till then--or (B) also being added--if only (A) has been administered or added up till then--and at least one prostaglandin (C) being added, before, or no later than at, the initiation of the platelet aggregation, so that the initiation and measurement of the platelet aggregation takes place in the presence of the ternary combination of (A), (B), each in the unchanged or in metabolized form, and (C).</p><p>Suitable as (A) are preferably compounds with a xanthine or pyrimidopyrimidine structure and as (B) is preferably O-acetylsalicylic acid. The method replaces elaborate and complicated tests on the human and animal body.</p>
7 schema:keywords Erythrocyte
8 IF
9 Prostaglandin-Endoperoxide Synthases
10 acid
11 aggregation
12 animal body
13 blood sample
14 compound
15 consequence
16 cyclooxygenase inhibitor
17 inhibitor
18 initiation
19 leukocyte
20 measurement
21 method
22 phosphodiesterase
23 phosphodiesterase inhibitor
24 platelet aggregation
25 prostaglandin
26 removal
27 sampling
28 vasoactive substance
29 xanthine
30 schema:name Method for detecting the antiaggregatory effect of vasoactive substances, specifically of inhibitors of phosphodiesterase and/or cyclooxygenase
31 schema:recipient https://www.grid.ac/institutes/grid.420214.1
32 schema:sameAs https://app.dimensions.ai/details/patent/US-4983514-A
33 schema:sdDatePublished 2019-04-18T10:26
34 schema:sdLicense https://scigraph.springernature.com/explorer/license/
35 schema:sdPublisher Nc11993a588234cdd844186ae5b08c497
36 sgo:license sg:explorer/license/
37 sgo:sdDataset patents
38 rdf:type sgo:Patent
39 N376589820cd947df88cf23729097a001 rdf:first Nb250aa1ca0c944a8ba4ea71a2518ea0b
40 rdf:rest rdf:nil
41 N8064615513e346de90d9de38143b3576 schema:name Klaus U. Weithmann
42 rdf:type schema:Person
43 Nb250aa1ca0c944a8ba4ea71a2518ea0b schema:name Dirk Seiffge
44 rdf:type schema:Person
45 Nc11993a588234cdd844186ae5b08c497 schema:name Springer Nature - SN SciGraph project
46 rdf:type schema:Organization
47 Ne949a5f9d9f34951a25cc366dcbffd1a rdf:first N8064615513e346de90d9de38143b3576
48 rdf:rest N376589820cd947df88cf23729097a001
49 anzsrc-for:3048 schema:inDefinedTermSet anzsrc-for:
50 rdf:type schema:DefinedTerm
51 sg:pub.10.1038/194927b0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052048522
52 https://doi.org/10.1038/194927b0
53 rdf:type schema:CreativeWork
54 sg:pub.10.1038/279799a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028958845
55 https://doi.org/10.1038/279799a0
56 rdf:type schema:CreativeWork
57 https://www.grid.ac/institutes/grid.420214.1 schema:Organization
 




Preview window. Press ESC to close (or click here)


...